Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine

ConditionMigraine

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age8-15

SponsorMuhammad Aamir Latif

About this trial

Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children of any gender

Aged 8-15 years

Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria

A history of ≥4 migraine attacks/month for the preceding 3 months

Disqualifiers

Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)

Known hypersensitivity or contraindications to flunarizine or propranolol

Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)

Non-compliance or inability to attend regular follow-ups

Trial design

Design model

Parallel

Treatments tested in this trial

Flunarizine
Drug
Patients will be receiving flunarizine beginning with 5 mg at bedtime and increasing it to 10 mg at bedtime after 1 month, over a 3-month treatment period.
Propranolol
Drug
Patient will be given propranolol beginning with 10 mg/24 hours and increase at the rate of 10 mg/week to the maximum of 60 mg/24 hour, over a 3-month treatment period.

Treatment groups

44 Participants

are divided into 2 treatment groups

Group A: Flunarizine groupExperimental treatment 1 intervention

Group B: Propranolol groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Reduction in migraine disability

Any reduction in migraine disability score measured by PedMIDAS will be labeled as reduction (efficacy).

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Muhammad Aamir Latif

Lead sponsor

RESnTEC, Institute of Research

Sponsor institution

Source ClinicalTrials.gov

Apply now